Tharimmune, Inc. | WebDisclosure

BRIEF

published on 04/30/2024 at 14:36, 6 months 21 days ago

Tharimmune to Engage Investors at Two Major Conferences in May

Biotechnology Investor Conferences Investor Engagement Tharimmune Inflammation And Immunology
BRIEF

published on 04/30/2024 at 14:36, 6 months 21 days ago

Tharimmune va impliquer les investisseurs lors de deux conférences majeures en mai

Biotechnologie Conférences Investisseurs Engagement Des Investisseurs Tharimmune Inflammation Et Immunologie
PRESS RELEASE

published on 04/30/2024 at 14:31, 6 months 21 days ago

Tharimmune To Participate in Two Upcoming Investor Conferences in May
Tharimmune to present at investor conferences in May 2024, showcasing developments in inflammation & immunology therapies. CEO to participate in Planet MicroCap Showcase: VEGAS 2024 & EF Hutton Annual Global Conference

Investor Conferences Tharimmune Inflammation Immunology Therapeutic Candidates
BRIEF

published on 04/23/2024 at 13:36, 6 months 28 days ago

Tharimmune obtient le droit de développer des conjugués anticorps-médicaments innovants

Tharimmune, Inc. Anticorps HER2/HER3 Conjugués Anticorps-médicament (ADC) Immunologie Du Cancer Nouvelles Thérapies
BRIEF

published on 04/23/2024 at 13:36, 6 months 28 days ago

Tharimmune Secures Rights to Develop Innovative Antibody Drug Conjugates

Tharimmune, Inc. HER2/HER3 Antibodies Antibody Drug Conjugates (ADCs) Cancer Immunology Novel Therapeutics
PRESS RELEASE

published on 04/23/2024 at 13:31, 6 months 28 days ago

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
Tharimmune, Inc. obtains rights from Washington University to develop human HER2 antibodies, expanding its pipeline of novel tunable antibodies for HER2 & HER3

Biotechnology Tharimmune Inc. Washington University HER2 Antibodies Novel Antibodies
PRESS RELEASE

published on 02/20/2024 at 14:01, 9 months 1 day ago

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
Tharimmune, Inc. announces successful Phase 1 trial completion for TH104, a promising treatment for chronic pruritus in primary biliary cholangitis. The study shows positive safety and tolerability profile aligned with previous findings

Tharimmune Inc. TH104 Phase 1 Trial Chronic Pruritus Primary Biliary Cholangitis
BRIEF

published on 02/20/2024 at 14:01, 9 months 1 day ago

Tharimmune announces positive Phase 1 results for TH104 and funding until 2025

Biotechnology Phase 1 Clinical Trial Funding TH104 Primary Biliary Cholangitis
BRIEF

published on 02/20/2024 at 14:01, 9 months 1 day ago

Tharimmune annonce les résultats positifs de la Phase 1 pour TH104 et le financement jusqu'en 2025

Biotechnologie Financement TH104 Essai Clinique De Phase 1 Cholangite Biliaire Primitive
PRESS RELEASE

published on 02/05/2024 at 14:30, 9 months 16 days ago

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. completes first patient dosing in Phase 1 clinical trial for TH104, an oral thin film targeting liver-related and pruritogenic inflammatory conditions. Topline data expected in 2Q24 with full readout shortly after. Company fully funded into 2025 for Phase 1 and 2 readouts

Phase 1 Clinical Trial Tharimmune Inc. TH104 Liver-related Conditions Pruritogenic Inflammatory Conditions

Published on 11/21/2024 at 17:35, 16 minutes ago

1upHealth Ranked Number 43 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500(TM)
Published on 11/21/2024 at 17:30, 21 minutes ago

SimpliGov and Proof Partner to Offer Online Notarization
Published on 11/21/2024 at 16:30, 1 hour 21 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 1 hour 50 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 1 hour 51 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight

View all ACCESSWIRE

Published on 11/21/2024 at 17:06, 45 minutes ago

Original-Research: PORR AG (von Montega AG): Kaufen
Published on 11/21/2024 at 17:02, 49 minutes ago

Original-Research: SBF AG (von Montega AG): Kaufen
Published on 11/21/2024 at 17:01, 50 minutes ago

Original-Research: Delticom AG (von Montega AG): Kaufen
Published on 11/21/2024 at 16:00, 1 hour 51 minutes ago

Director/PDMR Shareholding
Published on 11/21/2024 at 15:41, 2 hours 9 minutes ago

Edison issues report on Murray Income Trust (MUT)

View all EQS

Published on 11/21/2024 at 06:58, 10 hours 53 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 10 hours 53 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 10 hours 53 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 21 hours 43 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 22 hours 31 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE

News